MUC16 and ovarian cancer: Yet, Black patients had lower rates of elevated CA-125 levels at each stage compared with White patients, with 10.9% of Black patients with stage III to IV ovarian cancer having a nonelevated CA-125 level compared with 8.2% of White patients (Table 2).